Conclusion of funding agreement with the Polish Agency for Enterprise Development

Read More

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

Read More

Obtaining the status of Associate Partner within IPCEI Med4Cure

Read More

Conclusion of funding agreement with the National Centre for Research and Development

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

Ryvu Therapeutics S.A. Q1 2024 Financial Report

Read More

Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress

Read More

Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting

Read More

Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis

Read More

Ryvu project recommended for funding by the Polish Agency for Enterprise Development

Read More

Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error

Read More

Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank

Read More

Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting

Read More

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

Achievement of the second milestone under license agreement with Exelixis Inc.

Read More

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

Read More

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax

Read More

Registration of series K subscription warrants of the Company with the National Depository for Securities

Read More